Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Torben Noerup Nielsen who wrote (30260)	1/14/2000 10:13:00 AM
From: Alper H.YUKSEL	Read Replies (2) \| Respond to of 32384

I don't know about other shareholders, but I would be happy with 30. It's amazing to witness that this puppy has been transformed to a tiger now. The daily volume is much higher than it used to be. It must be institutions piling in, in anticipation of the conversion to profitability. BTW, we need 3 and change for the party. Which reminds me; have you seen the movie 'The Party' with Peter Sellers ?

To: Torben Noerup Nielsen who wrote (30260)	1/14/2000 10:15:00 AM
From: Henry Niman	Respond to of 32384

LGND has a poison pill provision to blunt any hostile takeover. Takeovers have been speculated on in the past, and the impact of LGND's many partnerships always comes up. I suspect that something could be worked out -sounds like two of their partners, GLX and SBH are again talking merger, while three other partners (WLA, PFE, AHP) also also in merger talks, so complex deals are certainly doable (and as most know, LGND has more than its share of complex deal (from the financial side, or even science side - they have 4 SERM deals alone). For LGND to sell out at $30, I would think that the Targretin breast cancer data would have to be pretty weak.